Somewhere in a landfill or floating in an ocean, there is a discarded drinks bottle made of PET plastic — the same material used in billions of food and beverage containers every year. Globally, roughly 500 billion PET plastic bottles are produced annually. The vast majority are not meaningfully recycled.
Now, researchers at the University of Edinburgh have found a way to turn that plastic waste into something else entirely: a drug that helps people with Parkinson's disease live better lives.
The Process: Bio-Upcycling
The technique, published in March 2026, uses a form of biological engineering called bio-upcycling. The team genetically modified Escherichia coli — the common bacterium used throughout biotechnology — to perform a sequence of chemical conversions that transform plastic into medicine.
Here's how it works:
- PET plastic is broken down into its chemical building block: terephthalic acid (TPA)
- Engineered E. coli bacteria take in the terephthalic acid and, through biological reactions programmed into their DNA, convert it into L-DOPA — levodopa, the primary pharmaceutical treatment for Parkinson's disease
The result: waste plastic in one end, medication out the other — using biology instead of fossil-fuel-derived chemistry.
Why L-DOPA?
L-DOPA (levodopa) has been the cornerstone of Parkinson's disease treatment since the 1960s. Parkinson's destroys the neurons that produce dopamine — the chemical messenger controlling smooth, coordinated movement. L-DOPA crosses the blood-brain barrier and is converted into dopamine in the brain, compensating for what Parkinson's has destroyed.
Millions of people worldwide take L-DOPA daily. Currently, it is produced using chemical synthesis processes that rely on fossil-fuel-derived precursors. The Edinburgh team's bio-upcycling route offers a fundamentally different manufacturing pathway — one built from waste rather than virgin resources.
The Results
- Production titre of 5.0 g/L of L-DOPA
- 84% conversion efficiency from industrial plastic waste
- First biological conversion of plastic waste into a neurological medicine ever demonstrated
The research is currently at proof-of-concept stage — demonstrated in laboratory conditions, not yet scaled to industrial production. However, the efficiency and yield figures are considered strong enough to justify serious commercial interest.
Beyond Parkinson's
The researchers believe the same bio-upcycling platform could be adapted to produce other high-value products from plastic waste — including flavourings, fragrances, and other pharmaceutical compounds. The underlying engineering approach is modular: the E. coli can, in principle, be reprogrammed to produce different outputs from the same plastic feedstock.
The global plastic crisis and the pharmaceutical industry's dependence on fossil-fuel chemistry are two of the most intractable problems in modern industrial production. A technology that addresses both simultaneously — turning a waste problem into medicine — represents exactly the kind of circular economy innovation that researchers have long been searching for.
The team at Edinburgh is now working to scale the process and explore routes toward commercial production.
In the meantime, somewhere, a discarded drinks bottle is waiting to become something more useful than landfill.
Sources: University of Edinburgh, March 2026 · news-medical.net, March 17, 2026 · dezeen.com, March 16, 2026 · Good News Network · Philly Voice
